Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine
-
Published:2024-05-28
Issue:1
Volume:24
Page:
-
ISSN:1471-2334
-
Container-title:BMC Infectious Diseases
-
language:en
-
Short-container-title:BMC Infect Dis
Author:
Xu Jiawei,Liu Yang,Qiu Wei,Li Wenwen,Hu Xiaoxiao,Li Xia,Fan Qiang,Tang Wenge,Wang Yujie,Wang Qing,Yao Ning
Abstract
Abstract
Background
To assess the immunogenicity of the current primary polio vaccination schedule in China and compare it with alternative schedules using Sabin or Salk-strain IPV (sIPV, wIPV).
Methods
A cross-sectional investigation was conducted at four sites in Chongqing, China, healthy infants aged 60–89 days were conveniently recruited and divided into four groups according to their received primary polio vaccination schedules (2sIPV + bOPV, 2wIPV + bOPV, 3sIPV, and 3wIPV). The sero-protection and neutralizing antibody titers against poliovirus serotypes (type 1, 2, and 3) were compared after the last dose.
Results
There were 408 infants completed the protocol. The observed seropositivity was more than 96% against poliovirus types 1, 2, and 3 in all groups. IPV-only groups induced higher antibody titers(GMT) against poliovirus type 2 (Median:192, QR: 96–384, P<0.05) than the “2IPV + bOPV” group. While the “2IPV + bOPV” group induced significantly higher antibody titers against poliovirus type 1 (Median:2048, QR: 768–2048, P<0.05)and type 3 (Median:2048, QR: 512–2048, P<0.05) than the IPV-only group.
Conclusions
Our findings have proved that the two doses of IPV with one dose of bOPV is currently the best polio routine immunization schedule in China.
Funder
Chongqing Health Commission and Chongqing Science and Technology Commission
the First Batch of Key Disciplines on Public Health in Chongqing
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Estivariz CF et al. Chapter 18: Poliomyelitis. Epidemiology and prevention of vaccine-preventable diseases, a.k.a. The Pink Book[M]. 14. Centers for Disease Control and Prevention, United States of America, 2021.
2. WHO. Poliomyelitis (polio)[EB/OL]. https://www.who.int/health-topics/poliomyelitis#tab=tab_1.
3. Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic Plan 2013–2018[EB/OL]. https://polioeradication.org/who-we-are/strategic-plan-2013-2018/.
4. Agency Of Disease Control And Prevention. Vaccination work specifications[EB/OL]. (2016-12-29)http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=8033406a995d460f894cb4c0331cb400.
5. WHO. Polio vaccines: WHO position paper – June 2022[J]. Wkly Epidemiol Rec. 2022;25(97):277–300.